Abstract: Novel solvates and crystal polymorphs of Ritonavir are disclosed, as well as methods of making them. Specific solvates of the compound include a formamide solvate and a partially desolvated solvate. Also disclosed are methods of making previously known forms of Ritonavir. Methods of using the novel forms of Ritonavir for the treatment of diseases, such as HIV-infection, are disclosed, as are pharmaceutical compositions and unit dosage forms comprising the novel forms of Ritonavir.
Type:
Grant
Filed:
May 1, 2003
Date of Patent:
April 17, 2007
Assignee:
TransForm Pharmaceuticals, Inc.
Inventors:
Sherry L. Morissette, Orn Almarsson, Stephen Soukasene
Abstract: The present invention concerns codeinone reductase from alkaloid poppy plants, the polynucleotides encoding the enzyme, transgenic plants transformed or transfected with polynucleotide(s) encoding codeinone reductase and to the production of alkaloids from transformed or transfected poppy plants.
Type:
Grant
Filed:
March 24, 2000
Date of Patent:
March 20, 2007
Assignee:
Johnson & Johnson Research Pty. Limited
Inventors:
Toni M. Kutchan, Meinhard H. Zenk, David G. Atkins, Anthony J. Fist
Abstract: The invention provides novel soluble conazole crystalline forms (e.g. itraconazole, posaconazole and saperconazole) that include salts, co-crystals and related solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, these conazole crystalline forms. Methods of using such compositions for the treatment or prevention of systemic and local fungal, yeast, and dermatophyte infections are also provided.
Type:
Grant
Filed:
May 30, 2003
Date of Patent:
July 18, 2006
Assignee:
TransForm Pharmaceuticals, Inc.
Inventors:
Jules Remenar, Michael MacPhee, Matthew Lynn Peterson, Sherry Lynn Morissette, Orn Almarsson
Abstract: The invention concerns paclitaxel solubilizers and formulations thereof with a high propensity to dissolve paclitaxel. The formulations of the invention reduce or obviate the need for the disadvantageous excipient Cremophor® EL. The formulations of the invention are useful for administering paclitaxel, its derivatives, or pharmaceutically acceptable salts or such derivatives to patients in need thereof. The formulations of the invention are suitable for parenteral, oral, local, or transdermal administration to mammals including humans, particularly for intravenous delivery.